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Nonsteroid anti-inflammatory drugs are often used to 
treat myalgias and arthralgias in enteroviral infections, 
but their effects on acute viral myocarditis are unknown. 
The effect of the nonsteroidal anti-inflammatory drug, 
ibuprofen, on acute viral myocarditis was studied in 75 
four week old male BALB/c mice infected with 1.75 x 
107 plaque-forming units of Coxsackie virus B3 on day 
O. Ibuprofen was given intraperitoneally at a dose of 15 
mg/kg body weight daily. The mice were assigned to four 
groups-Group I, 18 uninfected mice given ibuprofen 
on days 1 to 14; Group II, 18 infected, untreated mice; 
Group III, 20 infected mice given ibuprofen on days 1 
to 14; and Group IV, 17 infected mice given ibuprofen 
on days 7 to 14. Nine animals in Group I, eight in Group 
II and seven in Group III were killed on day 1; the 
remaining mice were killed on day 14. Heart viral cul•
tures and histologic analysis were done. Cultures at days 
7 and 14 were all negative. Inflammation and necrosis 
analyzed in each animal were graded 0 to 4, with grade 
4 representing widespread inflammation and necrosis. 
The emerging hypothesis that viral myocarditis may lead to 
chronic idiopathic dilated cardiomyopathy underscores the 
importance of a more complete understanding of the role 
of the initial viral infection. The viral infection incites the 
complex immunologic responses that lead to persistent myo•
cardial inflammation, fibrosis and, ultimately, cardio•
myopathy. Moreover, because specific treatment for most 
primary myocardial diseases does not exist, a further un•
derstanding of the pathogenesis of viral-initiated myocardial 
inflammation may lead to the development of therapy strat-
From the Loyola University Medical Center, Maywood, Illinois. This 
study was supported in part by the Earl M. Bane Charitable Trust Fund, 
Leroy, Illinois and was presented ih part at the 34th Annual Meeting of 
The American College of Cardiology, March 13, 1985, Anaheim, Cali•
fornia. Manuscript received April 18, 1985; revised manuscript received 
June 18, 1985, accepted June 27, 1985. 
Address for reprints: Maria Rosa Costanzo-Nordin, MD, Section of 
Cardiology, Loyola University Medical Center, 2160 South First Avenue, 
Maywood, Illinois 60153. 
© 1985 by the American College of Cardiology 
The heart was histologically normal in all 18 unin•
fected mice (Group I) given ibuprofen only. Inflamma•
tion and necrosis were not significantly different in Group 
II (infected, untreated) and Group III (infected, treated 
beginning day 1) mice killed at day 7. Inflammation 
scores of mice killed on day 14 were 2.1 ± 0.6 (Group 
II), 3.1 ± 0.7 (Group III) and 1.9 ± 1.0 (Group IV 
infected, treated days 7 to 14). Necrosis scores of mice 
killed on day 14 were 1.5 ± 0.8 (Group II), 3.0 ± 0.9 
(Group III) and 2.7 ± 1.1 (Group IV). When compared 
with Group II (infected, but flot treated), both inflam•
mation and necrosis were significantly worse in Group 
III (p < 0.01) and Group IV (p < 0.05). These results 
indicate that ibuprofen worsens ntyocardial inflamma•
tion and necrosis during acute viral myocarditis. This 
effect, not attributable to viral pet'ltlstence in the myo•
cardium, may be related to immunomodulating prop•
erties of ibuprofen on prostaglandin-sensitive mononu•
clear cells. 
(J Am Coll CardioI1985;6:1078-82) 
egies designed to treat the cause rather than ameliorate the 
congestive heart failure of dilated cardiomyopathy. 
The murine Coxsackie 83 myocarditis model is ideally 
suited for studies attempting to modify immune responses 
in acute and chronic myocarditis. Multiple lines of inves•
tigation have documented the evolution of this myocarditis 
from an acute viral syndrome to a chronic state of fibrosis•
a scenario that seems to parallel the pathophysiology of the 
human disease (1). After Coxsackie 83 infection, acute 
myocarditis ensues, but appropriate 8 cell and monocyte 
responses effect clearance of the virus. The myocardial his•
tologic changes that occur early are patchy and usually con•
sist of sporadk myonecrosis. However, a mononuclear in•
flammatory infiltrate persists in the heart of appropriate mouse 
strains for up to 6 months after the initial infection. His•
tologic analysis of these animals reveals fibrosis, dystrophic 
mineralization and myocardial hypertrophy. These progress 
to mural thrombi, myocardial disintegration and fibrotic 
scarring by 15 months (2). 
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The murine disease then appears to be two-phased. The 
initial phase is characterized by myocyte viral infection with 
reactive B cell, humoral antibody and monocyte responses, 
an appropriate rate of viral clearance by 10 days and a low 
fatality rate. The second, nonviral phase is characterized by 
absence of detectable virus in the face of mononuclear in•
filtrates that consist of monocytes, T lymphocytes and prob•
ably natural killer (NK) cells that perpetuate the disease to 
a terminal state of dilated cardiomyopathy (2,3). The dis•
sociation of the acute from the chronic phase bears a strong 
similarity to the human disease and has prompted the use 
of this model for the evaluation of immunopharmacologic 
interventions that may be efficacious in myocarditis•
cardiomyopathy. 
The effects of nonsteroid anti-inflammatory drugs on in•
flammatory responses are presumably based on the common 
denominator of their ability to perturb prostaglandin and 
lipooxygenase synthetic pathways (4). These drugs are usu•
ally considered to be a primary focus of therapeutic interest 
in diseases with either an infectious or a noninfectious in•
flammatory basis. Thus, we believed that an initial step in 
seeking means to modify viral heart inflammation would be 
to evaluate the role of nonsteroid anti-inflammatory drugs 
in altering myocardial necrosis and the unfavorable outcome 
of myocardial destruction in the murine model. 
Methods 
Animals. Seventy-five 3 week old male BALB/c mice 
were held for 7 days before the experiment in a single, self•
contained animal isolation unit to exclude animals with prior 
disease (Harlan Laboratory). The mice were maintained in 
disposable, filter-topped cages and handled with gloves by 
gowned and masked personnel. The intraperitoneal route 
was used for viral infection and all drug administration. All 
intraperitoneal injections were given in a 0.5 ml volume by 
tuberculin syringe with a 27 gauge needle after iodine-al•
cohol abdominal skin preparation. 
Drugs. Ibuprofen (kindly provided by Upjohn Labora•
tories) was diluted, on the day of injection, in Hanks' bal•
anced salt solution. 
Virus. Coxsackie virus B3 (Nancy strain) obtained from 
the American Tissue Culture Collection was grown on either 
human epidermoid cell line 2 (HEp-2) or VERO cells, ali•
quotted and maintained at -70°C until use. At the time of 
infection, seed virus was grown on either VERO or LLC 
monkey kidney-2 (LLC-MK-2) cells with Dulbecco's mod•
ified Eagle's medium, 12% fetal calf serum and gentamicin. 
Virus was harvested and adjusted to an inoculum of 1.75 
x 107 plaque-forming units per 0.5 ml Roswell Park Me•
morial Institute 1640. This infecting dose had been prede•
termined by serial dilution studies in identical strain, com•
parably aged mice that led to myocarditis in greater than 
95% of animals so challenged. 
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Treatment protocol. Ibuprofen or diluent only was given 
intraperitoneally daily at a dose of 15 mg/kg, the actual dose 
for each experiment being calculated from mouse weight at 
the time of infection. This drug amount is comparable with 
an average daily dose used in humans for synovial inflam•
mation. The date of viral infection was termed day 0; the 
day of study completion was day 14. On day 0, 55 mice 
were infected; 73 mice were assigned to one of four groups. 
Group I consisted of 18 noninfected mice treated with ibu•
profen on days 10 to 14, Group II consisted of 18 infected 
mice that were treated with diluent only for the duration of 
the experiment, Group III consisted of 20 infected mice 
given ibuprofen daily from days I through 14 and Group 
IV consisted of 17 mice infected at day 0 but receiving 
ibuprofen daily on days 7 through 14. On day 7, 24 mice 
were killed. The remaining survivors were killed on day 14. 
Histopathologic analysis. After cervical dislocation, the 
hearts were immediately removed for histopathologic anal•
ysis. Each heart was divided into two coronal sections. The 
basal section was snap-frozen and held at -70°C for viral 
assay. After thawing, the sections were minced with a sterile 
scalpel, suspended in I ml Roswell Park Memorial Institute 
1640 and homogenized in a glass tissue grinder. The sus•
pension was centrifuged at 8,000 rpm for 10 minutes at 4°C; 
supernatants harvested and frozen at - 70°C until assay. 
Serial lO-fold dilutions of heart homogenates in minimal 
essential medium were layered on confluent 72 hour old 
VERO cells that had been grown in 96 well microtiter plates 
(Falcon). Cytopathic effects were checked daily for 7 days 
and virus was determined by presence or absence of cell 
destruction. The remainder of the heart was immersed in 
buffered formalin and Bouin' s solution and processed by 
semi automated dehydration and stained with hematoxylin•
eosin and Masson's trichrome stains. 
Data analysis. The slides were coded and read inde•
pendently by two of the investigators blinded to experi•
mental group designations. Necrosis and inflammation were 
the two morphologic abnormalities analyzed, and each was 
graded according to the semiquantitative scoring system 
established by Woodruff and Woodruff (5) and modified by 
us (3). Basically, necrosis is scored 0 to 4, with a score of 
4 reflecting widespread necrosis. Inflammation was graded 
o to 4, with a grade of 4 representing 100 or more mono•
nuclear cells per low power field. 
Statistical analysis. The unpaired Student's t test and 
chi-square analysis were used to compare histologic abnor•
malities in experimental and control groups. 
Results 
Histologic scores in mice killed on day 7. One mouse 
died before the experiment and another on day I from a 
complication of the drug injection. There were no other 
complications secondary to drug injection during the study. 
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Table 1. Histologic Scores of 24 Mice Killed on Day 7 
Inflammation Necrosis 
Group I (n = 9) 0 0 
Group II (n = 8) 1.6 ± 0.6; 1.2 ± 0.9; 
(1-2.5) (0-2.5) 
Group III (n = 7) 1.8 ± 1.0; 1.4 ± 1.2; 
(1-3.5) (0-3) 
Results are expressed as mean :t SD; range of values shown in pa•
rentheses. Group I = noninfected mice given ibuprofen on days I to 14; 
Group II = infected mice given diluent only; Group III = infected mice 
given ibuprofen beginning on day I. 
One mouse in Group III was dead on day 14; three mice in 
Group IV died between days 12 and 14. These hearts could 
not be examined because of cannibalization. Nine animals 
in Group I, 8 in Group II and 7 in Group III were killed 
on day 7. Their histologic scores are shown in Table I. 
None of the drug-treated, but uninfected, mice had evidence 
of any inflammation or necrosis. The histologic changes in 
infected mice were not significantly different from those in 
infected, drug-treated mice. 
Histologic scores in mice killed on day 14. Nine ani•
mals in Group I, 10 in Group II, 12 in Group III and 14 in 
Group IV were killed on day 14. Inflammation and necrosis 
scores of the groups are depicted in Table 2. 
A spectrum of inflammatory infiltrates and myofibrillar 
necrosis (Fig. 1) was present in the three experimental 
groups. Only 2 of 10 mice in Group II (virus only) had 
severe inflammation (score::::: 3), whereas 9 mice (75%) in 
Group III (virus plus ibuprofen from day I) and 10 (71 %) 
in Group IV (virus plus ibuprofen from day 7) had severe 
inflammation (score::::: 3) (p < 0.05). Only one mouse in 
Group II had severe myofibrillar necrosis, whereas eight 
(66%) in Group III and nine (64%) in Group IV had severe 
necrosis (score::::: 3) (p < 0.05). Three animals (25%) in 
Group III and four (28%) in Group IV had severe, wide•
spread inflammation (score ::::: 4); four animals (33%) in 
Group III and four (28%) in Group IV had severe, wide-
Table 2. Histologic Scores of 45 Mice Killed on Day 14 
Inflammation Necrosis 
Group I (n = 9) 0 0 
Group II (n = 10) 2.1 ± 0.6; 1.5 ± 0.8 
(1-3) (0-3) 
Group III (n = 12) 3.1 ± 0.7*; 3.0 ± 0.9*; 
0.5-4) (1-4) 
Group IV (n = 14) 2.9 ± I.ot; 2.7 ± l.l t; 
(1-4) (1-4) 
*p < 0.01 compared with Group II; tp < 0.05 compared with Group 
II. Results are expressed as mean :t SD; range of values shown in paren•
theses. Groups I to III as in Table I. Group IV = infected mice given 
ibuprofen on days 7 to 14. 
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Figure 1. Cardiac inflammatory scores (top panel) and necrosis 
scores (bottom panel) of acute Coxsackie virus B3 myocarditis 
in 36 mice killed on day 14. Mice in Group II were infected but 
not treated with ibuprofen; those in Group III were infected and 
treated from day 1; those in Group IV were infected and treated 
on days 7 to 14 only. 
spread necrosis (score ::::: 4). No animal in Group I (drug 
only) had any inflammation or necrosis. Necrosis in the 
infected and drug-treated animals killed on day 14 was 
markedly different and characterized by extreme amounts 
of dystrophic calcification and gaping areas of necrosis sur•
rounded by dense bands of mononuclear infiltrates (Fig. 2). 
This could be contrasted with the thin bands of mononuclear 
infiltrates and much less calcification and focal density of 
necrosis in infected mice that were not drug-treated (Fig. 
3). Viral cultures of myocardium done at day 7 and day 14 
were negative in all experimental animals. 
Discussion 
The experiment presented here demonstrates conclu•
sively that ibuprofen, when given in the acute phase of 
murine myocarditis, exacerbates myocardial inflammation 
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and necrosis. The effects of ibuprofen on chronic myocar•
ditis have not been investigated, Although nonsteroid anti•
inflammatory drugs are commonly used to treat the myalgias 
and arthralgias of viral infection, we chose to study ibu•
profen for more basic than clinical reasons. The marked 
disparity between the drug-treated, virus-infected group and 
the virus-infected only group of animals should stimulate 
concern at the clinical level because many patients with 
viral infection are either purposely or coincidentally treated 
with nonsteroid anti-inflammatory drugs. 
Therapeutic interventions that alter Coxsackie virus 
B3 myocarditis. Other drugs have already been identified 
that alter Coxsackie virus B3 heart disease. Administering 
corticosteroids before Coxsackie virus B3 infection or as 
late as the sixth day after infection results in extensive my•
ocyte necrosis, viral persistence in the host and unusually 
high mortality (6). Presumably these agents inhibit the mi•
gration of inflammatory cells into the heart and also their 
ability to eliminate the virus. A more basic mechanism of 
A 
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Figure 2. Histologic sections. A, Cross section of heart (right and 
left ventricle) from a mouse infected with Coxsackie virus B3, 
treated with ibuprofen and killed on day 14. B, A IO-fold enlarge•
ment of portion of the right ventricle from the same heart shows 
extensive areas of necrosis and dystrophic calcification surrounded 
by dense mononuclear infiltrates. (Hematoxylin-eosin stain; orig•
inal magnification x 10 in A, x 100 in B. A reduced by 42%, B 
by 45%.) 
their deleterious influence on early viral infection may be 
their recently described ability to inhibit interleukin-2 syn•
thesis (7). Levamisole also has amplified cytotoxic activity 
Figure 3. Histologic sections. A, Cross section of heart (right and 
left ventricle) from an infected but untreated mouse killed on day 
14. B, A IO-fold enlargement of portion of the right ventricle 
shows small foci of myocarditis characterized by thin bands of 
mononuclear infiltrates and minimal necrosis and calcification. 
(Hematoxylin-eosin stain; original magnification x 10 in A, x 100 
in B. A reduced by 39%; B by 46%.) 
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of lymphocytes during Coxsackie virus B3 infection and 
has been associated with a significant increase in myocarditis 
when used in the murine Coxsackie virus B3 model (8). In 
contrast, therapeutic interventions that diminish T lympho•
cyte function have been shown to reduce myocardial in•
flammation associated with the chronic noninfectious phase 
of murine Coxsackie virus B3 myocarditis (5). These in•
terventions-for example, thymectomy-characteristically 
have universally impaired all T cell populations. Thus, a 
specific point of alteration of immunoregulation cannot be 
discriminated in these studies. Focused interventions against 
mononuclear sUbpopulations are not available, but altera•
tions of these subpopulations may well have relevance to 
our results. 
Possible immunomodulating effects of ibuprofen. The 
mechanism of immunomodulation by nonsteroidal anti-in•
flammatory drugs during Coxsackie virus B3 infection of 
myocardium is of great interest. A growing body of theoretic 
knowledge suggest that increased inflammation and ne•
crosis might occur in animals infected with Coxsackie virus 
B3 and treated with nonsteroid anti-inflammatory drugs. In 
the acute phase of myocarditis, the highly necrotic myo•
cardial lesions do not appear to be secondary to impaired 
viral clearance, a phenomenon shown to be dependent on 
relatively intact monocyte and humoral antibody function 
(9). Although we do not have serologic evidence of B cell 
Coxsackie virus B3 responses, the lack of detectable virus 
at both 7 and 14 days after infection implies that clearance 
mechanisms were operative. 
Ibuprofen, a phenylpropionate, blocks cyclooxygenase 
and lipooxygenase activity and subsequent formation of the 
inflammatory mediators prostaglandin E2 , prostaglandin F2 
and thromboxane A2 . Nonsteroid anti-inflammatory drugs 
also have inhibitory effects on neutrophils that are not de•
pendent on prostaglandin inhibition (4). These blocking 
mechanisms, recently shown to have cardioprotective ef•
fects during myocardial ischemia (10), should theoretically 
reduce viral-mediated inflammation and would not explain 
the marked disparity between the experimental groups in 
this study. Although the immunomodulating effects of ibu•
profen on prostaglandin-sensitive mononuclear subpopula•
tions have not been extensively studied, available evidence 
suggests that cyclooxygenase blockers may inhibit the ac•
tions of a population of prostaglandin-secreting, mononu•
clear suppressor cell populations (11,12). The prostaglandin 
E series can also inhibit the production or action of inter•
leukin-2 (13). Thus, the inhibition of prostaglandin E me•
diators by nonsteroid anti-inflammatory drugs could enhance 
amplification of a cytotoxic population as they also inhibit 
the emergence of an immunoregulatory suppressor cell pop•
ulation. The end result would strongly favor a marked in•
crease in both specific and autoimmune myocardial cell 
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necrosis during Coxsackie virus B3 infection (14). Con•
versely, the mechanism of increased necrosis may be on a 
more mechanistic basis. Inhibition of prostaglandin synthe•
sis may have negative effects on coronary flow or coronary 
vascular reactivity that enhance viral-induced cytotoxicity. 
Conclusions. The superimposition of a perturber of 
prostaglandin synthesis (ibuprofen) during the acute and 
early chronic phase of Coxsackie virus B3 murine myocar•
ditis leads to a marked exacerbation of both inflammatory 
and necrotic foci in the drug-treated animals. The Coxsackie 
virus B3 model appears useful for further study of both 
favorable and detrimental effects of immunomodulating drugs. 
The analysis of the morphologic outcomes after use of these 
immunomodulators may also lead to further understanding 
of inflammatory cell kinetics during viral infection of the 
heart and may identify important considerations in the use 
or nonuse of these drugs in appropriate clinical situations. 
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